Insider Selling: Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $38,000.00 in Stock

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bank Sa Swissquote also recently made the following trade(s):

  • On Thursday, January 11th, Bank Sa Swissquote sold 72,630 shares of Cytori Therapeutics stock. The stock was sold at an average price of $0.34, for a total value of $24,694.20.

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) opened at $0.35 on Friday. Cytori Therapeutics Inc has a 1-year low of $0.22 and a 1-year high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The company had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.04 million. During the same quarter in the previous year, the company posted ($0.26) earnings per share. research analysts predict that Cytori Therapeutics Inc will post -0.62 EPS for the current year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC increased its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,626,807 shares of the biotechnology company’s stock after buying an additional 355,504 shares during the period. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.41% of the company’s stock.

A number of equities research analysts have recently issued reports on CYTX shares. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 19th. Zacks Investment Research upgraded Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply